Objective: To quantify genetic overlap between migraine and ischemic stroke (IS) with respect to common genetic variation.
examined known genome-wide risk loci in the respective phenotypes. Using 2 methodologies, we then evaluated shared genetic risk for migraine with IS: (1) analysis of shared polygenic risk with subsequent estimation of genetic correlation between phenotypes and (2) detailed investigation of overlapping regions.
METHODS Standard protocol approvals, registrations, and patient consents. Ethics statement. For all study cohorts, all participants gave informed consent and local research ethics boards approved all protocols. 11, 15 Cohorts. Investigators of the IHGC study, a meta-analysis of GWAS data, enrolled 23,285 patients with migraine and 95,425 population-based or headache-free controls from 29 studies. 11 When possible, researchers considered subclassifications of migraine with (MA: 5,118 cases vs 74,239 controls) or without aura (MO: 7,107 cases vs 69,427 controls). The META-STROKE study consists of combined data from 15 GWAS of IS (12,389 cases vs 62,004 controls). 15 We used TOAST criteria 17 to classify IS as large artery stroke (LAS) (2,167 cases/49,159 controls from 11 studies), cardioembolic stroke (CE) (2,365 cases/ 56,140 controls from 13 studies), and small vessel disease (SVD) (1,894 cases/51,976 controls from 12 studies) (tables e-1 and e-2 on the Neurology ® Web site at Neurology.org). 11, 15 We removed overlapping controls between the migraine and stroke samples from deCODE, WTCCC2 (B58C and KORA), and the Rotterdam studies from the stroke datasets for polygenic score analyses, cross-phenotype spatial mapping (CPSM), and correlation analyses to avoid inflation of statistics.
Genome-wide association studies. Both the IHGC migraine 11 and METASTROKE 15 studies consisted of independently performed genome-wide single nucleotide polymorphism (SNP) genotyping using standard technologies and imputation to HapMap release 21 or 22 CEU phased genotype 18 or 1000 Genome reference panels. Investigators contributed summary statistical data from association analyses using frequentist additive models for metaanalysis after application of appropriate quality control measures (e-Methods). Subtle differences in allele frequencies between migraine and stroke could lead to deviation from the expected test statistic. Thus, as a final quality control step, we meta-analyzed results from the IHGC study and the METASTROKE study and constructed quantile-quantile plots (figure e-1).
Statistical analysis. For analysis of previously discovered risk loci for IS or migraine, we extracted relevant loci from the literature and the 2 described consortia. 11, 15 We examined all SNPs within a window of 650 kb surrounding the original reported risk SNP (coordinates from human genome build hg18) and reported the most significant p values of all genotyped or imputed SNPs within this window. We applied Bonferroni correction for association, integrating all tested SNPs for IS risk loci (650 tested SNPs), migraine risk loci (1,175 tested SNPs), and MO risk loci (213 tested SNPs) with resulting p value thresholds of 7.69E-5, 4.25E-5, and 2.30E-4, respectively.
Polygenic scores reveal combined effects of multiple nonsignificant variants derived from a derivation sample and tested in an independent replication sample. We derived polygenic scores for multiple p value cutoffs (0.5, 0.25, 0.1, 0.05, 0.01, 0.001, and 0.0001) in derivation samples. Further, we performed testing on summary statistics using the grs.summary function of the gtx package for R, a technique previously used in multiple studies, which estimates the polygenic component with high reliability. 19 We use the term replication to describe analyses across phenotypes.
Use of linkage disequilibrium (LD) pruned data (r 2 . 0.25) ensured approximate independence of SNPs. We retained the SNP with the lowest p value in an independent region and calculated the proportion of variance explained in the testing set by the polygenic scores using Nagelkerke's pseudo R 2 . Outcome measures include the p value of the association of the polygenic score in the testing dataset and the variance explained.
CPSM identifies genomic windows exhibiting similar association patterns across 2 phenotypes using a signal processing approach. CPSM allows analysis of pleiotropy across multiple diseases. Peak heights serve as an intuitive measure for description of shared risk loci in different phenotypes. This method corrects for background noise in the p value distribution and is thus superior to comparisons of single p values. We computed Pearson covariance between p values from 2 traits across a 60-kb sliding window. In each iteration, the window slides to the next SNP; thus, we obtained a covariance coefficient for each SNP in the analysis. We then detected signal peaks across the genome in the covariance trace and calculated the signal s n for a given SNP with index n, position b n (base pairs), and association p values p1, n , p2 ,n for 2 phenotypes as follows:
x 5 2 logð10Þp 1;j ; .: 2 logð10Þ p 1;k y 5 2 logð10Þp 2;j ; .. 2 logð10Þ p 2;k
where each b i Є b j ,.b k is the position of SNP i within the window of SNPs j,.,k containing SNPn. For a given window size d (base pairs), the window of SNPs j,.,k is defined such that j is the smallest SNP index where b n 2b j # d 2 and k is the largest SNP index where b k 2b n # d 2 . After constructing the CPSM signal for all SNPs, we corrected for strong associations identified in only one phenotype by permuting the association p values for one phenotype 1,000 times while holding the other phenotype constant, and then recalculating CPSM signals. From the total set of 2,000 permutation signals (1,000 per phenotype), we subtracted the upper 0.95 quantile at each SNP as the background signal threshold from the observed covariance as a correction. We then identified regions of shared association as peaks above the 99.95 (approximately corresponding to a height of 1.5) percentile of the covariance signal. We highlighted regions with a height .2.5 (corresponding to approximately 99.985 percentile) and with a height .5 (corresponding to approximately 99.998 percentile). CPSM only provides a signal when the effect in 2 traits is the same, implying shared causality in the discovered regions.
Utilizing a recently developed framework for polygenic analyses and based on the number of SNPs, the dataset sample sizes, and estimates of disease prevalence and pseudo-heritability, we estimated the power to detect an association indexing on a given degree of genetic correlation between the 2 phenotypes. We used the same framework, including p values from polygenic analysis, to estimate the overall degree of genetic correlation between each of the IS and migraine phenotypes, a posteriori to the polygenic analysis. We estimated genetic correlation in both the forward direction (using results from polygenic analysis of IS and subtypes as a discovery sample and migraine and subtypes as a replication sample) and the reverse direction (using results from the polygenic analysis from migraine and subtypes as a discovery sample and stroke and subtypes as a replication sample) to evaluate consistency of results using the estimateCorrFromP method. An implementation of the procedure was downloaded from http://sites.google.com/site/fdudbridge. This method approximates SNP correlation from cross-disorder applications of polygenic scores and can be compared to GREML-SNP genetic correlation. All analyses used R statistical software (http://www. R-project.org). Using stroke prevalence data from the British Heart Foundation for IS 20 (1.7% in the United Kingdom) and the proportional incidence of IS events from all stroke events in the OXVASC study 21 (59%), we estimated the prevalence of IS (;1%). We then used the proportion of IS subtypes (CE, LAS, or SVD) from a meta-analysis of population-based incidence studies 22 to estimate the prevalence of each subtype. We estimated stroke heritability on a liability scale. 23 Although we acknowledge that migraine prevalence may vary across countries, we estimated migraine prevalence to be 17% for all migraine, 11% for MO, and 5% for MA based on published data. 1, 24 Migraine heritability estimates vary in the literature, with MA being highest. We chose heritability measures of 0.65 for MA 25 and 0.61 for MO 26 and a more conservative measure of 0.57 for all migraine.
RESULTS Information on clinical subtypes was available for 12,225 (52.5%) of the migraine and for 6,426 (51.9%) of the IS patients (tables e-1 and e-2). We identified 38,338 potentially overlapping controls and excluded them from analyses where necessary. QQ plots revealed no inflation of test statistics (lambda inflation factors below 1.05 in all analyses of migraine subtypes vs all IS; figure e-1 and e-Methods).
All migraine. We first evaluated risk loci identified in previous GWAS on IS or its subtypes, 15 in all migraine 11 and vice versa. Although we identified several variants reaching nominal association (p , 0.05), when controlling for all tested SNPs, none of the Results from polygenic score analysis using ischemic stroke as a discovery phenotype tested variants surpassed Bonferroni-corrected p value thresholds (tables e-3 and e-4).
Polygenic scores. Scores derived from LAS, CE, and SVD each showed significant associations with all migraine (figure 1, tables 1 and e-5) with replication p values ranging from 2.7E-9 for LAS to 0.017 for SVD. Explained variance ranged from 0.005% to 0.03% (figure 1, table 1). Conversely, polygenic scores derived from all migraine significantly associated with LAS, CE, and SVD (figure 2, tables 1 and e-5) with replication p values between 8E-9 (replication in LAS) and 0.03 (replication in SVD) and an explained variance between 0.008% and 0.065% (figure 2, tables 1 and e-5). Calculated estimates of genetic correlation between all migraine and IS ranged from approximately 3% for correlation with all IS to 38% for correlation with LAS (table 2) .
CPSM analysis. The most significant loci reaching an arbitrary peak height cutoff of 2.5 for CPSM are summarized in table 3 (full results, table e-6). Using this height cutoff, there were 5 shared loci for all IS and all migraine with the strongest signal at chromosome 12q24 (height 5 7.2). For LAS and all migraine, we found 3 shared loci, with the LMOD2-WASL region on chromosome 7q31 showing the strongest signal (height 5 7.2). CE and SVD showed 8 and 3 shared loci with all migraine, respectively (maximum height, 4.94 for CE and all migraine; 3.99 SVD and all migraine).
Migraine without aura (MO).
A single variant in the 9p21 region, previously associated with LAS, 14 surpassed the Bonferroni-corrected threshold for association with MO (p 5 4.0E-5). Focusing on 2 Table 1 Polygenic score results
Discovery set
Replication set variance explained is the pseudovariance explained by the risk score model in the replication dataset (3100 to display percentage). Odds ratios were calculated from the estimated coefficient for regressing the response onto the risk score and are given as an increase of 1 standard deviation of the polygenic score.
loci previously known to be associated with MO but not MA, 11 we identified no variants surpassing the Bonferroni-corrected p value threshold (table e-4).
Polygenic scores. Scores derived from all IS, LAS, CE, and SVD each showed significant associations with MO (figure 1, tables 1 and e-5); replication p values ranged from 6.43E-28 for LAS polygenic score to 1.47E-5 for SVD polygenic score. The highest percentage of explained variance occurred for scores derived from LAS and CE (0.157% and 0.111%, respectively), and was higher in MO than in all migraine across all p value cutoffs (figure 1, B and C). Conversely, polygenic scores derived from MO significantly associated with all IS, LAS, CE, and SVD (figure 2, tables 1 and e-5) with replication p values between 6E-24 (replication in LAS) and 0.004 (replication in SVD) and an explained variance between 0.015% and 0.198% (figure 2, tables 1 and e-5). Estimates of genetic correlation with IS were markedly higher than observed for all migraine (estimates ranged from 25% for correlation with all IS to 83% for correlation with LAS; table 2).
CPSM analysis. Using a cutoff of 2.5, we detected 4 shared loci between MO and all IS. MO and LAS shared 3 loci, with the strongest signal at chromosome 9p21 (signal height, 7.7). CE and MO shared 6 loci (maximum height 5 3.87), and MO and SVD shared 4 loci (2 loci reaching maximum heights of 6.7 and 6.3). The former was near the CISD2 gene on chromosome 4q24, the latter in a gene-rich region on chromosome 17q21 including the Tau locus (tables 3 and e-6). Migraine with aura (MA). None of the variants previously associated with IS surpassed the Bonferronicorrected p value threshold of 7.69E-5 when tested for association with MA. There were no genome-wide significant loci 11 for MA. Polygenic scores. Scores derived from IS, LAS, and CE all showed significant associations with MA (figure 1, tables 1 and e-5) with replication p values ranging from 0.002 for the all IS polygenic score to 0.04 for the CE polygenic score. Explained variance ranged from 0.010% (LAS) to 0.012% (IS). Polygenic scores derived from MA significantly associated with all IS and LAS (figure 2, tables 1 and e-5) with replication p values of 0.0017 and 0.0005, and an explained variance of 0.013% and 0.023%, respectively. Estimates of genetic correlation ranged from 8% for correlation with CE to 28% for correlation with LAS (table 2) .
CPSM analysis. We found several shared regions between MA and stroke subtypes. Using a cutoff of 2.5, we found 2 shared loci between all IS and MA with a maximum height of 3.15 and 2 loci shared between LAS and MA with a maximum height of 3.53 in the LMOD2/WASL gene region. CE and MA shared no loci using this cutoff and SVD and MA shared 1 locus with a maximum height of 2.83 (tables 3 and e-6). DISCUSSION We demonstrated that the combined contributions of common genetic variants at a number of loci influence risk for both migraine and IS. This is supported by results from 4 investigative approaches: (1) analysis of common variants at loci reaching genome-wide significance for potential signal overlap; (2) investigation of shared genetic load using polygenic score models; (3) estimation of genetic correlation between disease subtypes using data derived from these models; and (4) highlighting regions of shared risk by analysis of covariance patterns between phenotypes using CPSM. We found stronger signal overlap between MO and IS than between MA and IS; overlap is stronger for LA and CE stroke than for SVD. Finally, we identified several individual loci with a strong signal for association with both phenotypes.
Polygenic scores, estimates of genetic correlation, and CPSM results all demonstrated a stronger genetic overlap of IS with MO compared to MA. Polygenic scores from MO replicated in overall IS and IS subtypes across a wide range of p value cutoffs, while scores derived from IS behaved similarly when tested in MO. Scores derived from MA demonstrated weaker association with IS. The variance explained by polygenic scores of each IS subtype was consistently higher for MO (figures 1 and 2). Also, estimates of genetic correlation with IS and its subtypes were consistently higher for MO than for MA (table 2) .
Unexpectedly, CPSM revealed that the number of loci reaching a peak height .2.5 was larger for MO and IS than for MA and IS (table 3). Recent epidemiologic studies suggest an association between IS risk and MA but not MO, 3, 6 but other data suggest that patients with MO are at increased risk of IS. 4 One potential explanation is that genetic risk for MA may be more restricted to rare variants not captured by GWAS strategies as suggested by the larger number of genome-wide significant loci for MO compared to MA despite comparable sample sizes. 11 However, estimated heritability for MA is as least as high as for MO. 25, 26 Larger samples together with sequencing efforts or rare variant assays might help to determine whether rare variants indeed influence MA risk and whether the same variants also contribute to IS risk. The same might be true for SVD, for which there are no existing identified genome-wide loci. Hence, we might have underestimated genetic overlap between migraine subtypes and SVD.
We found particularly strong genetic overlap for migraine with LAS and CE. Polygenic scores analyses showed the strongest overlap with LAS for all forms of migraine regardless of whether polygenic scores were derived from LAS and tested in migraine or vice versa. In a recent small population-based study of 360 migraineurs and 617 controls, researchers reported no association between migraine and intima media thickness, 27 but more advanced stages of atherosclerosis were not assessed. Most previous studies examining the relationship between migraine and IS did not distinguish among stroke subtypes. Migraineurs display enhanced platelet aggregation, 9 which together with other factors might contribute to overlap with LAS. Abbreviations: CE 5 cardioembolic; CI 5 confidence interval; IS 5 ischemic stroke; LAS 5 large artery stroke; MA 5 migraine with aura; MO 5 migraine without aura; SVD 5 small vessel disease. Genetic correlation is estimated using results from polygenic score analysis, taking into account the number of single nucleotide polymorphisms used, number of subjects in the analysis, and prevalences and heritability estimates of the 2 phenotypes. The forward experiment uses the stroke subtype as the discovery set and the migraine subtype as the testing set. The reverse experiment uses the migraine subtype as the discovery set and the stroke subtype as the testing set. Analysis of loci previously shown to reach genome-wide significance for association with migraine showed several variants nominally associated with IS or its subtypes and vice versa. In fact, single variants reached a high threshold of statistical significance, e.g., variants on 9p21, a major risk locus for LAS 14, 15 reaching very low p values in MO (table e-3) . However, in all instances index SNPs for the tested phenotype were in poor LD (r 2 , 0.4) with published risk SNPs making it unlikely that the same variants confer risk to both stroke and migraine.
CPSM analysis revealed several chromosomal regions with strong evidence for genetic overlap between migraine and IS pointing to shared biological mechanisms, including loci already shown to be associated with either migraine or stroke such as a chromosome 12 locus previously implicated in IS, coronary artery disease, hypertension, diabetes, and blood cell traits including platelet count. 19, [28] [29] [30] Interestingly, MRVI1 on chr11, another locus previously associated with platelet aggregation, 31 showed genetic overlap between migraine and IS, adding to previous data suggesting a shared role of platelet dysfunction in migraine and IS. 9 Mendelian randomization studies and interventional studies are needed to determine the exact role of platelets in mediating such genetic risk. We also demonstrated genetic overlap between migraine and IS at chromosome 9p21 especially for LAS.
There was genetic overlap at loci not reaching genome-wide significance in migraine or stroke GWAS. A shared locus for all migraine and LAS on 7q31.32 includes the LMOD2-WASL gene region. LMOD2 encodes leiomodin2 that antagonizes tropomodulin, an actin-capping protein. 32 WASL is implicated in stabilizing endothelial adherens junctions, 33 and is important for synapse development. 34 We also found overlapping regions for SVD with MO including a locus on 4q24 that encompasses MANBA, which encodes b-mannosidase. Mutations in MANBA are associated with epileptic encephalopathy 35 and leukoencephalopathy. 36 This region also contains SLC9B2, previously associated with essential hypertension, 37 a major risk factor for SVD. A second shared risk locus between MO and SVD points to MAPT, the gene encoding tau protein on chromosome 17.
We used the largest collections of GWAS data currently available for migraine 11 and IS, 15 with 4 different but complementary approaches for analysis of genetic overlap including novel methodology (CPSM). 38 Polygenic scores reflect multiple variants with very small effect sizes distributed across the whole genome whereas our analysis of known loci and CPSM analysis focus on specific broader regions with highly correlated p values. Overall, results were remarkably consistent. Estimates of genetic correlation between phenotypes were similar in forward and reverse direction as were results of polygenic scores.
Our study also has limitations. First, some patients with MA might have been misdiagnosed with IS and vice versa. However, this should have shifted the results towards a stronger overlap between IS and MA, whereas we found stronger overlap for MO. Thus, diagnostic misclassification is unlikely to contribute substantially to our results. Second, some patients may have had both conditions. We can largely exclude ascertainment bias favoring the selection of patients with comorbidity substantiated by differences in age structure between migraineurs and stroke patients. Third, lacking individual level data, we cannot exclude some overlap in controls. We carefully checked for any potential overlap in controls and excluded samples where appropriate. Bias resulting from overlapping controls would not explain the differences observed between clinical subphenotypes. Finally, we are missing information on clinical subtypes for a substantial proportion of patients, reducing power in subgroup analyses, but this should not result in systematic bias to explain observed differences. Future studies on larger samples should further explore genetic overlap with rare causes of IS such as dissections, which were not considered separately in this study. Abbreviations: CE 5 cardioembolic; LAS 5 large artery stroke; IS 5 ischemic stroke; MA 5 migraine with aura; MO 5 migraine without aura; SNP 5 single nucleotide polymorphism; SVD 5 small vessel disease. All loci with a height .2.5 are shown. For full results, refer to table e-6. Note that coordinates are mapped to NCBI36/hg18. The IS and migraine subtype where the calculation was performed as well as chromosomal band, chromosomal location, peak SNP, and peak height are displayed. Genes in the region denote all genes found within the specified region. a Direction of effect is given for the peak SNP. b All loci with height .5.
Our data provide genetic insights from GWAS meta-analyses into shared mechanisms of migraine and IS and may in part explain the relationship between these 2 common neurovascular disorders.
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